Corteva (NYSE:CTVA) Given New $16.00 Price Target at JPMorgan Chase & Co.

Corteva (NYSE:CTVA) had its target price reduced by equities research analysts at JPMorgan Chase & Co. from $19.00 to $16.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 72.47% from the company’s previous close.

CTVA has been the subject of a number of other research reports. Mizuho set a $16.00 price objective on Corteva in a research note on Thursday. KeyCorp raised shares of Corteva from a “sector weight” rating to an “overweight” rating and set a $17.00 price target for the company in a research report on Wednesday, October 7th. Weiss Ratings lowered shares of Corteva from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, August 3rd. Bank of America boosted their price objective on shares of Corteva from $90.00 to $96.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Corteva in a research note on Friday, October 2nd. Fifteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Corteva has a consensus rating of “Moderate Buy” and an average target price of $56.27.

Corteva Trading Up 0.9%

Shares of NYSE CTVA traded up $0.09 during midday trading on Friday, reaching $9.28. The company had a trading volume of 14,193,068 shares, compared to its average volume of 8,320,709. Corteva has a one year low of $9.01 and a one year high of $90.97. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average price is $38.81 and its 200-day moving average price is $69.88. The stock has a market cap of $6.19 billion, a PE ratio of 6.14, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58.

Institutional Investors Weigh In On Corteva

A number of large investors have recently made changes to their positions in CTVA. Parkside Financial Bank & Trust lifted its stake in shares of Corteva by 3.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 3,729 shares of the company’s stock worth $316,000 after purchasing an additional 116 shares during the period. HB Wealth Management LLC raised its stake in shares of Corteva by 0.5% in the second quarter. HB Wealth Management LLC now owns 23,822 shares of the company’s stock worth $2,018,000 after buying an additional 128 shares during the period. Wilkerson Advisory Group LLC lifted its position in shares of Corteva by 6.7% during the 1st quarter. Wilkerson Advisory Group LLC now owns 2,112 shares of the company’s stock valued at $177,000 after buying an additional 133 shares in the last quarter. Aviance Capital Partners LLC lifted its position in shares of Corteva by 1.3% during the 1st quarter. Aviance Capital Partners LLC now owns 11,008 shares of the company’s stock valued at $922,000 after buying an additional 137 shares in the last quarter. Finally, Pinnacle Wealth Management Advisory Group LLC grew its stake in shares of Corteva by 3.2% during the 2nd quarter. Pinnacle Wealth Management Advisory Group LLC now owns 4,762 shares of the company’s stock valued at $403,000 after acquiring an additional 147 shares during the period. 81.54% of the stock is currently owned by institutional investors.

Corteva News Roundup

These are some of the CTVA news items that stood out recently:

• Positive Sentiment: Corteva said new products delivered strong sales growth and highlighted cost reductions as part of its recovery plan. These factors may help offset market weakness, though the company cautioned that Brazil’s conditions are weighing on its outlook. Article: Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut
• Negative Sentiment: The main concern is persistent weakness in Brazil, including excess inventories and pricing pressure, which Corteva’s CEO expects to continue weighing on results. The company lowered its 2026 adjusted EPS guidance to $0.76–$0.80, below the cited analyst consensus of $1.07. Reports also point to lower volumes and competitive pricing contributing to weak quarterly performance. Article: Corteva shares slide after Brazil weakness prompts annual profit forecast cut Article: Corteva’s Q3 Earnings Miss Estimates on Brazil Weakness, Sales Lag
• Negative Sentiment: A law firm announced an investigation into possible securities-law violations related to Corteva. The announcement is not a finding of wrongdoing, but may add uncertainty for investors. Article: Securities fraud investigation announcement

About Corteva

Corteva, Inc. is an agricultural science company that develops and supplies products and services for farmers. Its business focuses on seeds and crop protection, including technologies intended to help improve crop performance and manage weeds, insects, and plant diseases. Its seed portfolio includes corn, soybean, and other crop varieties, sold under brands such as Pioneer and Brevant. Corteva’s crop protection offerings include herbicides, insecticides, fungicides, and biological products, alongside digital tools and services that support farm decision-making.